{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.7","upperLimit":"33.7","value":"28.9"},{"groupId":"OG001","lowerLimit":"23.5","upperLimit":"29.9","value":"27.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"354"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy. Median OS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received T-DXd 5.4 mg/kg via IV infusion every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG000","title":"T-DXd"},{"description":"Participants received Investigator's choice single-agent chemotherapy (capecitabine 1000 or 1250 mg/m\\^2 orally twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles, paclitaxel 80 mg/m\\^2 via IV infusion qw in 3-week cycles or nab-paclitaxel 100 mg/m\\^2 via IV infusion qw for 3 weeks followed by 1-week rest period in 4-week cycles) until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The HER2-low population included the subset of participants in the ITT population with HER2 IHC 2+/ISH- and IHC 1+ as determined per the IRT data for HER2 IHC expression.","reportingStatus":"POSTED","timeFrame":"From date of randomization until death due to any cause, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)","title":"Overall Survival (OS) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population","type":"SECONDARY","unitOfMeasure":"months"}